focus -WSS

focus

author：hotspot 2025-10-01 00:17:28 - browse：722

A young boy died in a trial for Pfizer’s experimental gene therapy for Duchenne muscular dystrophy, the company told patient advocates Tuesday.

The boy was enrolled in Daylight, a trial studying the treatment in boys aged 2 or 3. The boy had received the therapy early last year, Pfizer told the advocates in a note posted online by Parent Project Muscular Dystrophy.

Pfizer said the boy died of cardiac arrest, but that it was still working to understand what happened and the exact cause.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： In age of alternative facts, a scholarly course on calling out crap
Next article： Medicare explains how it will choose drugs for negotiation

WSS

After affirmative action ruling, medical educators look to 'holistic review'

NYU Langone launches private ChatGPT for its health care data

Cancer drug shortages should be causing more outrage

AstraZeneca challenges Medicare drug negotiation program

BioMarin wins approval for gene therapy to treat hemophilia A

Apple is now the first public company to be valued at $3 trillion

entertainment

focus

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.

leisure time

Sports medicine is finally prioritizing gender equality

Neuroscience startup Neumora files for IPO

How to save PrEP access — and even expand it

Trump demands the U.S. pay no more for drugs than other countries … again

Anesthesiologist group: stop taking Ozempic before surgery

Cancer drug shortages should be causing more outrage

The high cost of giving birth even with insurance

Alkermes shareholders re

ChatGPT in medicine: STAT answers readers' burning questions

Medical leaders decry Supreme Court decision on affirmative action

hotspot

DIEP, the 'gold standard' of breast reconstruction, is under threat

United colonoscopy coverage change 'may cost lives,' doctors say

Diversity in medical illustrations gets boost from Chidiebere Ibe

How to make AI work for medicine

AstraZeneca bets AAV gene therapy will still deliver the goods

Psychedelics group wrestles with new pharma identity

entertainment

hotspot

explore

hotspot